New Wave Wealth Advisors LLC Purchases New Position in Bristol Myers Squibb Company $BMY

New Wave Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 12,183 shares of the biopharmaceutical company’s stock, valued at approximately $697,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Capital Square LLC raised its stake in Bristol Myers Squibb by 60.9% during the 3rd quarter. Capital Square LLC now owns 8,184 shares of the biopharmaceutical company’s stock valued at $511,000 after acquiring an additional 3,099 shares in the last quarter. OceanIQ Capital LLC grew its stake in shares of Bristol Myers Squibb by 2.5% in the third quarter. OceanIQ Capital LLC now owns 8,170 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 200 shares in the last quarter. Jackson Square Capital LLC grew its stake in shares of Bristol Myers Squibb by 4.6% in the third quarter. Jackson Square Capital LLC now owns 9,925 shares of the biopharmaceutical company’s stock worth $619,000 after purchasing an additional 435 shares in the last quarter. Kaufman Rossin Wealth LLC increased its holdings in shares of Bristol Myers Squibb by 37.8% during the third quarter. Kaufman Rossin Wealth LLC now owns 5,159 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 1,416 shares during the period. Finally, Narus Financial Partners LLC increased its holdings in shares of Bristol Myers Squibb by 14.6% during the third quarter. Narus Financial Partners LLC now owns 7,606 shares of the biopharmaceutical company’s stock valued at $475,000 after purchasing an additional 970 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

NYSE:BMY traded down $0.68 during mid-day trading on Monday, reaching $59.07. 5,438,418 shares of the stock were exchanged, compared to its average volume of 12,073,516. The business has a fifty day moving average price of $63.55 and a 200 day moving average price of $60.30. The firm has a market capitalization of $120.66 billion, a PE ratio of 13.01, a PEG ratio of 0.30 and a beta of 0.19. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same period in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.56 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Truist Financial reissued a “buy” rating and set a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. JPMorgan Chase & Co. raised their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.88.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.